ingest
cdrApp
2018-03-15T16:49:04.223Z
d591f2cd-3da7-4b31-9dd8-ee27dcb6a3ee
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2018-03-15T16:49:54.263Z
Setting exclusive relation
addDatastream
MD_TECHNICAL
fedoraAdmin
2018-03-15T16:50:05.699Z
Adding technical metadata derived by FITS
addDatastream
MD_FULL_TEXT
fedoraAdmin
2018-03-15T16:50:28.517Z
Adding full text metadata extracted by Apache Tika
modifyDatastreamByValue
RELS-EXT
fedoraAdmin
2018-03-15T16:50:50.858Z
Setting exclusive relation
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-05-17T13:47:17.557Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-11T00:21:43.149Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-07-17T20:21:44.134Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-08T19:48:44.717Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-15T16:57:36.710Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-08-16T20:00:16.636Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-09-21T17:25:42.099Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-09-26T20:35:51.072Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2018-10-11T21:14:26.449Z
modifyDatastreamByValue
MD_DESCRIPTIVE
cdrApp
2019-03-20T14:39:13.814Z
Aaron
Winn
Author
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
Summer 2017
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George M.
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George M.
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
University of North Carolina at Chapel Hill
Degree granting institution
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics; Hospital Markets; Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics, Hospital Markets, Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Health Policy and Management
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George M.
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Aaron
Winn
Creator
Department of Health Policy and Management
Gillings School of Global Public Health
The Impact of Market Structure on Oncology Care
The market structure of oncology care is undergoing dramatic consolidation. Little work has examined how market structure impacts oncology care. This study has three objectives: (1) investigate the effect of market structure on geographic access to care for patients receiving infused chemotherapy; (2) investigate the impact of market structure on Medicare reimbursement for patients receiving infused chemotherapy; and (3) evaluate how the market structure impacts the speed of diffusion in the use of new high- and low-value treatments for patients.
Using a 20% sample of Medicare Fee-For-Service claims from 2008 to 2014, we identified a cohort of 142,770 patients receiving infused chemotherapy for cancer and 89,096 new users of chemotherapy. We assessed relationships between 1) competition and the number of chemotherapy-administering physicians within 25, 50, and 75 miles of the patient’s zip code and the distance traveled to receive chemotherapy, 2) competition and Medicare expenditures for infused chemotherapy, and 3) competition and diffusion of new treatments.
We find that a one standard deviation increase in logged Herfindahl-Hirschman Index (HHI) (i.e., market becoming less competitive) increases the average distance traveled from 100 to 112 miles and decreases the average number of physicians within 75 miles from 346 to 312 physicians. When examining spending, we find that spending decreases as markets become less competitive at the claim service-line level and the day level but is not impacted when looking at total spending in the six months following treatment initiation. Finally, we examined five newly approved medications or existing medications with new indications: (nab-paclitaxel, bendamustine, degarelix, temsiroliimus, and bevacizumab) and find that the impact of competition on the diffusion of a new treatment varies by treatment. Nab-paclitaxel, a lower value drug, diffuses slower as markets become less competitive, whereas bendamustine, a higher value drug, diffuses faster as markets become less competitive. We do not find significant associations between market competition and drug diffusion for the other drugs studied.
Competition impacts patients’ geographic access to care. The association between competition and healthcare spending and diffusion of medications is not consistent. Future research should examine how competition impacts patients’ access to care in other clinical areas, drivers for increased spending in consolidated areas, and the quality of care is impacted by competition for cancer patients.
2017-08
2017
Health care management
Public policy
Public health
Health Economics; Hospital Markets; Mergers
eng
Doctor of Philosophy
Dissertation
University of North Carolina at Chapel Hill Graduate School
Degree granting institution
Stacie
Dusetzina
Thesis advisor
Ethan
Basch
Thesis advisor
George M.
Holmes
Thesis advisor
Nancy
Keating
Thesis advisor
Justin
Trogdon
Thesis advisor
text
Winn_unc_0153D_17348.pdf
uuid:7f19c7de-b1ec-4bc2-9c2b-9636595e880f
2019-12-31T00:00:00
2017-09-01T19:36:08Z
proquest
application/pdf
945241